When a trial is stopped for futility, it can either be that the treatment doesn’t work, or the control arm has faired much better than expected meaning the trial itself was not sufficiently powered.
the greater the difference between control and treated, the less patients you need recruited to show a statistically significant clinical benefit.
so again it all lies in the data... If there is a benefit there that is worth exploring, then Novartis may run that larger trial to find out once and for all... though it may be for all cause ARDS.
it will take a while to get that trial up and running though... nothing ever moves quickly .. this COVID trial was at warp speed compared to others.
still hopeful in the CLBP results.
Goodluck all
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-452
-
- There are more pages in this discussion • 624 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |